•The U.S. FDA approved BYSANTI (milsaperidone) as a first-line therapy for manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults.
•BYSANTI is a New Chemical Entity (NCE) that belongs to the class of atypical antipsychotics.
•Ravelin Properties REIT announced it does not expect to make principal or interest payments on its 9.00% convertible unsecured subordinated debentures.
•The maturity date for the 9% debentures is February 28, 2026.
•The REIT is internally managed and listed on the TSX under the symbol RPR.UN.
